Ablynx has signed a collaboration agreement with Centocor R&D, Inc. under which the companies will perform research funded by Centocor. Applying the unique properties of Nanobodies, the two companies will work jointly on novel approaches for administration and delivery of Nanobody-based therapeutics. The financial terms of the collaboration are not disclosed.

Nanobodies are a novel class of therapeutic proteins that combine the beneficial features of conventional antibodies with desirable properties of small molecule drugs. Because of their unique structure and high stability, Nanobodies can address target opportunities that are beyond the reach of conventional antibodies.

Dr. Mark Vaeck, chief executive officer of Ablynx said, “We are delighted to engage in this collaboration with Centocor who are a pioneer in the development of therapeutic antibodies. Through this partnership we create a unique opportunity for Ablynx, by combining our own know-how on the Nanobody platform with the world-class expertise of Centocor, who are considered as the benchmark in therapeutic antibody development.”